Inactive Instrument

Reviva Pharmaceuticals Holdings, Inc. Nasdaq

Equities

TZAC

US76152G1004

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 19:34:43 28/05/2024 BST			5-day change	1st Jan Change
1.385 ^USD	-72.08%		-10.14%	-43.28%

04:12pm	Riviva Pharmaceuticals Prices $3 Million Offering of Stock, Warrants; Shares Slump	MT
05-15	Reviva Pharmaceuticals Holdings, Inc. Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia	CI

Tenzing Acquisition Corp. Reports Earnings Results for the Second Quarter Ended August 31, 2020

October 14, 2020 at 10:12 pm

Tenzing Acquisition Corp. announced earnings results for the second quarter ended August 31, 2020. For the second quarter, the company announced operating loss was USD 525,924 compared to USD 94,110 a year ago. Net loss was USD 516,032 compared to net income of USD 274,320 a year ago. For the half year, operating loss was USD 790,865 compared to USD 165,245 a year ago. Net loss was USD 671,798 compared to net income of USD 612,746 a year ago.

Latest news about Reviva Pharmaceuticals Holdings, Inc.

Riviva Pharmaceuticals Prices $3 Million Offering of Stock, Warrants; Shares Slump	03:12pm	MT
Reviva Pharmaceuticals Holdings, Inc. Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia	05-15	CI
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Reviva Pharmaceuticals Holdings, Inc. to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference	05-13	CI
Reviva Pharmaceuticals Holdings, Inc. Gains Alignment with U.S. Food and Drug Administration on its Registrational Phase 3 Program for Brilaroxazine in Schizophrenia	04-15	CI
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-15	CI
Reviva Pharmaceuticals Closes $30 Million Registered Direct Offering	11-20	MT
Reviva Pharmaceuticals Holdings, Inc. announced that it has received $2.999942 million in funding	11-19	CI
Sector Update: Health Care Stocks Slightly Advancing Late Afternoon	11-16	MT
Sector Update: Health Care Stocks Rise in Thursday Afternoon Trading	11-16	MT
Sector Update: Health Care	11-16	MT
Reviva Pharmaceuticals Launching $30 Million Registered Direct Offering; Shares Fall	11-16	MT
Reviva Pharmaceuticals to Seek Acquisitions	11-16	CI
Reviva Pharmaceuticals Holdings, Inc. announced that it expects to receive $2.999942 million in funding	11-14	CI
Reviva Pharmaceuticals Holdings Q3 Loss Widens	11-14	MT
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
HC Wainwright Raises Reviva Pharmaceuticals' Price Target to $20 From $10, Keeps Buy Rating	31/10/23	MT
Sector Update: Health Care Stocks Gain Late Afternoon	30/10/23	MT
Sector Update: Health Care	30/10/23	MT
Reviva Shares Surge After Late-Stage Schizophrenia Trial Meets Primary Endpoint	30/10/23	MT
Top Midday Gainers	30/10/23	MT
Reviva Pharmaceuticals Says Phase 3 RECOVER Trial of Brilaroxazine in Adults With Schizophrenia Meets Primary Endpoint	30/10/23	MT
Reviva Pharma's schizophrenia drug succeeds in late-stage study	30/10/23	RE
Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia	30/10/23	CI
Sector Update: Health Care Stocks Flat to Lower Pre-Bell Monday	25/09/23	MT

Chart Reviva Pharmaceuticals Holdings, Inc.

Duration

Period

Chart Reviva Pharmaceuticals Holdings, Inc.

More charts

Company Profile

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Companyâs pipeline focuses on the central nervous system, respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimerâs disease (BPSD), and Parkinsonâs disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).

Sector

Biotechnology & Medical Research

Calendar

29/05/2024 - Lytham Partners Spring Investor Conference

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+50.63%	63.85B
IQVIA HOLDINGS INC.	-2.30%	41.83B
LONZA GROUP AG	+40.01%	40.47B
CELLTRION, INC.	-10.22%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.68%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.69B
BIO-TECHNE CORPORATION	+3.13%	12.73B
UNITED THERAPEUTICS CORPORATION	+22.00%	12.11B
MEDPACE HOLDINGS, INC.	+27.97%	12.07B

Other Biotechnology & Medical Research